Literature DB >> 17230418

Hypersusceptibility to invasive pneumococcal infection in experimental sickle cell disease involves platelet-activating factor receptor.

Martha L Miller1, Geli Gao, Tamara Pestina, Derek Persons, Elaine Tuomanen.   

Abstract

Children with sickle cell disease have a 600-fold increased incidence of invasive pneumococcal disease. Platelet-activating factor receptor (PAFr) mediates pneumococcal invasion, and up-regulation of PAFr on chronically activated endothelia could contribute to increased bacterial invasion. Mice transplanted with sickle cell bone marrow developed more extensive infection, and 57% died, compared with 16% of wild-type mice. Histopathological analysis revealed that sickle cell mice expressed significantly more PAFr on endothelia and epithelia. Pharmacological blockade or genetic deletion of PAFr protected sickle cell mice from mortality. We conclude that PAFr plays an important role in hypersusceptibility to pneumococcal infection in sickle cell disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17230418     DOI: 10.1086/510626

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

Review 2.  Secondary bacterial infections in influenza virus infection pathogenesis.

Authors:  Amber M Smith; Jonathan A McCullers
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

Review 3.  The co-pathogenesis of influenza viruses with bacteria in the lung.

Authors:  Jonathan A McCullers
Journal:  Nat Rev Microbiol       Date:  2014-03-03       Impact factor: 60.633

Review 4.  Preventing and treating secondary bacterial infections with antiviral agents.

Authors:  Jonathan A McCullers
Journal:  Antivir Ther       Date:  2011

Review 5.  Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

6.  Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Authors:  Jeffrey D Lebensburger; Thad Howard; Yunming Hu; Tamara I Pestina; Geli Gao; Melissa Johnson; Stanislav S Zakharenko; Russell E Ware; Elaine I Tuomanen; Derek A Persons; Jason W Rosch
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

7.  Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease.

Authors:  Jason W Rosch; Angela R Boyd; Ernesto Hinojosa; Tamara Pestina; Yunming Hu; Derek A Persons; Carlos J Orihuela; Elaine I Tuomanen
Journal:  J Clin Invest       Date:  2010-01-19       Impact factor: 14.808

8.  The platelet activating factor receptor is not required for exacerbation of bacterial pneumonia following influenza.

Authors:  Jonathan A McCullers; Amy R Iverson; Raelene McKeon; Peter J Murray
Journal:  Scand J Infect Dis       Date:  2007-06-21

Review 9.  Bacterial-Host Interactions: Physiology and Pathophysiology of Respiratory Infection.

Authors:  A P Hakansson; C J Orihuela; D Bogaert
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

10.  Age-associated inflammation and toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia.

Authors:  Ernesto Hinojosa; Angela R Boyd; Carlos J Orihuela
Journal:  J Infect Dis       Date:  2009-08-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.